Investigations of potential alterations of IgA-bacterial binding have been a starting point to study different diseases, including Inflammatory Bowel Disease (IBD; Palm et al., 2014; Viladomiu et al., 2017; Kabbert et al., 2020; Rengarajan et al., 2020; Shapiro et al., 2021), postmenopausal breast cancer (Goedert et al., 2018), allergy (Dzidic et al., 2017), and pathogen infections (Džunková et al., 2016). This evidence concerns the gene CD79A and inflammatory bowel disease.